Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses ongoing research efforts to develop natural anti-androgenetic alopecia treatments using bioactive compounds from medicinal plants but reports no new clinical results.

This study reports that Korean adolescents with androgenetic alopecia tend to have milder symptoms than adults and a higher prevalence of family history of alopecia.

This study found that a hair serum containing Acanthus ebracteatus extract improved hair regrowth in men with androgenic alopecia, increasing hair count and density of anagen hairs over a 6-month period, with combination treatments showing early effectiveness.

In this study, cyclic ADP-ribose (cADPR) treatment in human hair follicle dermal papilla cells was associated with increased intracellular calcium retention and activated anagen-related signaling without causing significant cytotoxicity, indicating its potential impact on hair growth processes.

This study highlights the potential of polymeric micelles in enhancing the targeted delivery and efficacy of treatments for androgenetic alopecia, by offering improved retention on the scalp, extended release, and reduced systemic side effects compared to conventional therapies like minoxidil and finasteride.

This study suggests that EDA-A2 induces apoptosis in hair follicles by increasing DKK-1 expression, implicating EDA2R signaling as a potential therapeutic target for androgenetic alopecia.

This letter provides historical insights into the origin of the term "androgenetic alopecia," highlighting its use by Dr. Orentreich in the late 1950s based on his autograft studies.

This study developed a chalcone-based molecule that significantly increased tyrosinase inhibition and solubility, showing potential as a safe and effective skin depigmenting and antiaging agent, with supportive epigenetic and antioxidant properties observed in vitro.

This review discusses recent advances in understanding the Eda pathway's role in developmental biology, and highlights ongoing trials and areas for further research, including Eda's potential involvement in cell processes and disease.

This study found that applying both dehydrothermal treatment and carbodiimide crosslinking improved the mechanical properties of porcine acellular dermal matrix scaffolds without added cytotoxicity, suggesting potential applications in tissue engineering.

This study found that alginate beads containing monoolein demonstrated promising potential for managing wet wounds by better absorbing excess exudate and delivering adenosine locally, favoring drug localization in damaged porcine skin compared to an aqueous solution without affecting skin viability.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

Caffeine may help hair growth in hereditary hair loss.

This article discusses the potential role of oral DHEA, available as a 'dietary supplement' in the US, in COVID-19 morbidity and mortality, calling for clinical trials to assess its safety.

This study reported that acupuncture combined with topical Aloe vera and celery gel reduced hair loss from alopecia androgenetica after 28 days of treatment.

This letter to the editor comments on the association between androgenetic alopecia and increased scalp hardness, exploring the possible role of phosphodiesterase inhibitors but provides no new clinical results.

This review explores the role of advanced glycation end products in skin aging and their interaction with oxidative stress, but reports no new clinical findings.

This study used molecular docking to analyze the binding affinities of quercetin and kaempferol, plant-derived flavonoids, showing they have promising interaction profiles with JAK3 kinase and moderate binding with 5-alpha reductase type 2, suggesting potential as topical treatments for androgenetic alopecia.

This article reviews the causes and current treatment options for androgenetic alopecia, reporting no new clinical findings and highlighting the need for more therapeutic choices.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This review discusses Amphiregulin (AREG) as a potential target for treating fibrotic disorders and cancer, highlighting its role in disease progression and promising results in preclinical studies and early trials.

This study found that krh/krh rats serve as a suitable model for non-inflammatory acne and that adapalene treatment decreased open comedones and altered lipid metabolism and cytokine production in these rats.

This study found that increased mRNA expression of the Ectodysplasin-A2-Receptor, observed across multiple species and tissues, may exacerbate inflammation during aging, suggesting potential benefits of blocking EDA2R/EDA-A2 signaling.

This review highlights the potential of amphiregulin as a therapeutic target, noting its role in both fibrotic and malignant diseases, and discusses promising early findings but reports no new clinical results.

This study using human and animal models found that adipose-derived stem cell exosomes promoted hair growth and counteracted dihydrotestosterone's inhibitory effects, suggesting potential therapeutic applications for androgenetic alopecia.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.